The HDDC2 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt HDDC2 expression in the human HT29 colorectal adenocarcinoma cell line. This polyclonal pool provides a heterogeneous loss-of-function model for studying the negative regulation of innate immune signaling. The CRISPR/Cas9 system introduces targeted gene disruptions, yielding a population with diverse editing outcomes at the HDDC2 locus. This model enables functional assessment of HDDC2 deficiency without clonal selection biases.
The HT29 cell line is a well-established human colorectal adenocarcinoma model with epithelial morphology. Derived from a primary colon tumor, HT29 cells retain intestinal epithelial characteristics, making them suitable for gastrointestinal research. They are widely used in studies of colorectal cancer, inflammatory bowel disease, and innate mucosal immunity, and respond robustly to cytokines and microbial ligands such as LPS. Their adherent growth and signaling responses make them ideal for interrogating Toll-like receptor and NF-??B pathways.
HDDC2 encodes an HD domain-containing phosphohydrolase that negatively regulates NF-??B-mediated innate immunity. Mechanistically, it reduces TRAF6 ubiquitination downstream of TLR4 and IL-1R, thereby dampening TAK1 and IKK complex activation. This limits I??B?? phosphorylation and degradation, preventing NF-??B nuclear translocation and reducing transcription of pro-inflammatory cytokines such as IL-6, IL-8, and TNF. Upstream stimuli including IL-1??, TNF-??, and LPS engage this cascade via MyD88 and IRAK1, with HDDC2 fine-tuning the response.
In HT29 intestinal epithelial cells, HDDC2 disruption likely relieves tonic inhibition of NF-??B, creating a primed state for innate immune responses. This polyclonal knockout model enables dissection of HDDC2’s role in epithelial homeostasis and the balance between mucosal tolerance and inflammation. Dysregulated NF-??B is implicated in colorectal cancer, inflammatory bowel disease, and autoimmune disorders, making this model valuable for disease research and therapeutic screening. The polyclonal nature avoids clonal artifacts and better reflects in vivo heterogeneity.
Key applications include elucidating negative NF-??B regulation in intestinal epithelia, assessing HDDC2’s impact on colorectal cancer proliferation and invasion, and screening anti-inflammatory compounds. Compatible assays span western blotting for phospho-I??B??, NF-??B reporter assays, RT-qPCR for IL6, IL8, and TNF, co-immunoprecipitation of TRAF6 ubiquitination, and cytokine ELISA. Cell proliferation and migration/invasion assays extend functional analysis. This polyclonal knockout population is a versatile tool for immunology and oncology research. For assistance, contact Ascent Research.
